Form 4: Macrogenics Exec Vests, Sells Shares for Tax

Macrogenics Senior VP Jeffrey Peters reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Summary

• Jeffrey Stuart Peters, Senior VP, GC, and Secretary of Macrogenics Inc. (MGNX), reported changes in beneficial ownership.
• On February 7, 2026, 6,001 restricted stock units (RSUs) vested, converting into common stock.
• Concurrently, 2,317 shares were disposed of at $1.81 per share to cover tax withholding obligations related to the RSU vesting.
• On February 8, 2026, an additional 8,999 restricted stock units (RSUs) vested, converting into common stock.
• An additional 3,474 shares were disposed of at $1.81 per share for tax withholding purposes.
• The RSUs vesting on February 7, 2026, were the first installment of a 18,000 RSU grant from February 7, 2025.
• The RSUs vesting on February 8, 2026, were the first installment of a 27,000 RSU grant from February 8, 2024.
• Following these transactions, Peters directly owns 22,920 shares of common stock, 11,999 derivative securities (remaining RSUs from the 02/07/2025 grant), and 9,000 derivative securities (remaining RSUs from the 02/08/2024 grant).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices rather than a significant change in company fundamentals or executive confidence.

Positives

• Vesting of restricted stock units indicates continued employment and long-term incentive alignment for a key executive.
• The acquisition of shares through RSU vesting increases the executive's direct ownership in the company.

Negatives

• The disposition of shares, even for tax purposes, reduces the executive's direct shareholding.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, reflecting executive compensation structures that often include equity awards like Restricted Stock Units (RSUs). The vesting and subsequent tax-related sales are common events in executive compensation.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures across all industries for insider transactions.
• The RSU vesting and tax-related sales are typical mechanisms for executive equity compensation, aligning with common practices in the biotechnology and pharmaceutical sectors, where long-term incentives are crucial for retaining key talent like Senior VPs and General Counsels.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but also alignment of executive interests with shareholders through equity ownership.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Future vesting installments of the 18,000 RSU grant (granted 02/07/2025) will occur on the second and third anniversaries of the grant date.
• Future vesting installments of the 27,000 RSU grant (granted 02/08/2024) will occur on the second and third anniversaries of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related sales) and does not provide new information that would fundamentally alter the investment thesis for Macrogenics. It's a neutral event that doesn't warrant a change in investment recommendation.

Keywords

Macrogenics, MGNX, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Beneficial Ownership, Jeffrey Peters